Spyre Therapeutics is deprioritizing its TL1A antibody monotherapy program in rheumatoid arthritis after phase 2 results failed to meet the company’s success bar. The update follows SPY072’s evaluation and comes as TL1A has been a target of growing industry interest due to its role in inflammatory signaling. The report indicates the company will narrow its development focus rather than pursue continued monotherapy efforts based on the mid-stage data. The move reflects how quickly clinical strategy can change once efficacy signals fall short, even when the target biology remains validated. For trial planners and alliance partners, the reprioritization highlights the risk profile of cytokine-axis antibodies, where patient selection, dosing, and comparator choice can materially influence readouts. The setback also pressures the wider TL1A competitive landscape by demonstrating that blocking the pathway does not guarantee clinical benefit across RA populations.